• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer

    5/4/22 8:00:00 AM ET
    $ADAP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADAP alert in real time by email

    PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 04, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Dr. Joanna (Jo) Brewer as Chief Scientific Officer (CSO) effective immediately.

    "Jo Brewer is an exceptional scientific leader, and I am delighted that she has accepted the newly created CSO role, leading our ongoing scientific research, and developing future autologous and allogeneic therapies," said Adrian Rawcliffe, Adaptimmune's Chief Executive Officer. "Jo has a strong track record of building successful teams, driving innovation in cell therapy, as she worked on all of our autologous clinical programs and developed our allogeneic iPSC T-cell therapy platform. She has played a crucial role in our collaborations with Astellas and Genentech."

    Most recently, Dr. Brewer served as Senior Vice President, Allogeneic Research at Adaptimmune since December 2019. In this role, she built the Allogeneic Research organization from the ground up and took the concept of iPSC-derived allogeneic T-cell therapies from an idea into the potential for an allogeneic candidate in the clinic. Prior to her SVP role, Dr. Brewer held a series of senior managerial roles within Adaptimmune's research organization. Her experience in immunotherapy and cell therapy at Adaptimmune and its predecessor companies spans more than 20 years and includes roles across the breadth of discovery. Before focussing solely on the allogeneic platform for the last three years, Dr. Brewer was one of the founding scientists at Adaptimmune who built multiple research teams working on the development of SPEAR T-cell therapies including NY-ESO (transitioned to GSK in 2018), ADP-A2M4 and ADP-A2AFP, as well as early next-generation approaches including the ADP-A2M4CD8 construct. Prior to joining Adaptimmune in 2009, Dr. Brewer held positions at Avidex, Medigene, and Immunocore. She holds a master's degree in Natural Sciences, and a Ph.D. in cellular signalling, both from the University of Cambridge, U.K.

    About Adaptimmune 

    Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.

    Forward-Looking Statements 

    This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2021, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances. 

    Adaptimmune Contacts: 

    Media Relations: 

    Sébastien Desprez — VP, Corporate Affairs and Communications 

    T: +44 1235 430 583 

    M: +44 7718 453 176 

    [email protected] 

    Investor Relations: 

    Juli P. Miller, Ph.D. — VP, Investor Relations 

    T: +1 215 825 9310 

    M: +1 215 460 8920 

    [email protected] 



    Primary Logo

    Get the next $ADAP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADAP

    DatePrice TargetRatingAnalyst
    7/30/2024$4.00Buy
    H.C. Wainwright
    5/30/2024$3.15Sector Outperform
    Scotiabank
    3/24/2023$3.60Buy
    Bryan Garnier
    1/3/2023$5.00Neutral → Buy
    Guggenheim
    11/9/2022$9.00Neutral → Buy
    Mizuho
    9/22/2021$6.00 → $7.00Equal-Weight
    Wells Fargo
    9/13/2021$6.00 → $7.00Market Perform
    SVB Leerink
    9/7/2021$5.00 → $6.00Market Perform
    SVB Leerink
    More analyst ratings

    $ADAP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Adaptimmune Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Adaptimmune Therapeutics with a rating of Buy and set a new price target of $4.00

      7/30/24 6:31:41 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scotiabank initiated coverage on Adaptimmune Therapeutics with a new price target

      Scotiabank initiated coverage of Adaptimmune Therapeutics with a rating of Sector Outperform and set a new price target of $3.15

      5/30/24 7:25:43 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bryan Garnier initiated coverage on Adaptimmune Therapeutics with a new price target

      Bryan Garnier initiated coverage of Adaptimmune Therapeutics with a rating of Buy and set a new price target of $3.60

      3/24/23 9:09:04 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Bertrand William C Jr

      4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)

      2/20/25 5:35:34 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Brewer Joanna Elizabeth

      4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)

      2/20/25 5:34:48 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Patient Supply Officer Lunger John

      4 - Adaptimmune Therapeutics PLC (0001621227) (Issuer)

      2/20/25 5:33:25 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADAP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adaptimmune Reports Q1 Financial Results and Provides Business Update

      TECELRA® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced$4.0 million Tecelra net sales in Q1 2025Instituting 2025 Tecelra full year sales guidance of $35-$45 millionLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated in 2026Adaptimmune had Total Liquidity1 of $60 million as of March 31, 2025; call at 8 a.m. EDT today Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reported financial results and provided a business update for the first quarter ended March

      5/13/25 7:30:00 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

      Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 7, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter of 2025, before the US markets open on Tuesday, May 13, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m. EDT that same day.The press release will be available in the investor section of Adaptimmune's corporate website. A live webcast and replay can be accessed at https://www.gowebcasting.com/14032. Call in information is as follows: 1-833-821-0158 (US or Canada) or 1-647-8

      5/7/25 12:00:00 PM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune Provides Q4 and Full Year 2024 Business Update

      TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achievedLete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programsAt the end of 2024, Adaptimmune had Total Liquidity1 of $152 millionEvaluating all strategic options to maximize shareholder valuePhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company redefining the treatment of solid tumor cancers with cell therapy,

      3/20/25 7:00:00 AM ET
      $ADAP
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care